Wall Street brokerages expect Abeona Therapeutics Inc (NASDAQ:ABEO) to announce earnings of ($0.23) per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Abeona Therapeutics’ earnings. The lowest EPS estimate is ($0.26) and the highest is ($0.19). Abeona Therapeutics reported earnings per share of ($0.13) during the same quarter last year, which would indicate a negative year-over-year growth rate of 76.9%. The company is expected to issue its next earnings results on Wednesday, November 21st.

According to Zacks, analysts expect that Abeona Therapeutics will report full-year earnings of ($0.88) per share for the current year, with EPS estimates ranging from ($0.97) to ($0.74). For the next financial year, analysts forecast that the firm will report earnings of ($0.81) per share, with EPS estimates ranging from ($1.13) to ($0.34). Zacks’ EPS averages are a mean average based on a survey of analysts that follow Abeona Therapeutics.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Friday, August 10th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.06). The firm had revenue of $0.82 million for the quarter, compared to analyst estimates of $1.81 million. Abeona Therapeutics had a negative return on equity of 23.02% and a negative net margin of 881.74%.

Several research analysts have recently weighed in on ABEO shares. Zacks Investment Research cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 15th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Abeona Therapeutics in a research report on Thursday, September 13th. Maxim Group reaffirmed a “buy” rating and set a $35.00 price objective on shares of Abeona Therapeutics in a research report on Friday, August 10th. ValuEngine raised Abeona Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 2nd. Finally, BidaskClub raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 2nd. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $26.80.

Hedge funds and other institutional investors have recently modified their holdings of the stock. FMR LLC boosted its position in Abeona Therapeutics by 47.7% during the second quarter. FMR LLC now owns 7,094,307 shares of the biopharmaceutical company’s stock valued at $113,509,000 after purchasing an additional 2,291,016 shares during the last quarter. Millennium Management LLC boosted its position in Abeona Therapeutics by 5.3% during the second quarter. Millennium Management LLC now owns 964,839 shares of the biopharmaceutical company’s stock valued at $15,437,000 after purchasing an additional 48,583 shares during the last quarter. BlackRock Inc. boosted its position in Abeona Therapeutics by 0.3% during the first quarter. BlackRock Inc. now owns 1,873,472 shares of the biopharmaceutical company’s stock valued at $26,884,000 after purchasing an additional 5,094 shares during the last quarter. Nexthera Capital LP boosted its position in Abeona Therapeutics by 69.6% during the second quarter. Nexthera Capital LP now owns 626,804 shares of the biopharmaceutical company’s stock valued at $10,029,000 after purchasing an additional 257,304 shares during the last quarter. Finally, UBS Group AG boosted its position in Abeona Therapeutics by 36.5% during the first quarter. UBS Group AG now owns 152,081 shares of the biopharmaceutical company’s stock valued at $2,182,000 after purchasing an additional 40,680 shares during the last quarter. 76.24% of the stock is owned by hedge funds and other institutional investors.

Shares of ABEO stock traded up $0.37 on Monday, hitting $10.40. 629,959 shares of the stock were exchanged, compared to its average volume of 886,407. The stock has a market capitalization of $613.67 million, a P/E ratio of -15.76 and a beta of 1.10. Abeona Therapeutics has a fifty-two week low of $9.66 and a fifty-two week high of $22.00.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

See Also: Bond

Get a free copy of the Zacks research report on Abeona Therapeutics (ABEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.